Orionis Biosciences

About:

Orionis Biosciences operates in the healthcare industry focusing on biotechnology business & innovation.

Website: http://orionisbio.com

Top Investors: Cormorant Asset Management, Novartis, Solasta Ventures, Excel Venture Management, Empire Angels

Description:

Orionis Biosciences operates in the healthcare industry focusing on the biotechnology business and innovation. The company is an early-stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical needs – with an initial internal focus in oncology and immunotherapies. Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution.

Total Funding Amount:

$79.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2015-01-01

Founders:

Nikolai Kley

Number of Employees:

11-50

Last Funding Date:

2022-10-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai